ArticleInternational journal of molecular sciences2021

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome.

Petra Gorombei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.